/PRNewswire/ Foresight Diagnostics, a leader in minimal residual disease (MRD) detection technology, announced today that three studies utilizing their.
Adding brentuximab vedotin to chemotherapy in pediatric Hodgkin lymphoma produced results that have been hailed as a paradigm shift and have just led to FDA approval for this new indication.
The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results. The findings, published in The New England Journal of Medicine, additionally showed the brentuximab vedotin (Adcetris, Seagen) regimen to be well tolerated.